KAI1/CD82, a tetraspanin protein, was first identified as a metastasis suppressor in prostate cancer. How loss of CD82 expression promotes cancer metastasis is unknown. Restoration of CD82 expression to physiological levels in the metastatic prostate cell line PC3 inhibits integrinmediated cell migration and invasion, but does not affect integrin expression. Integrin-dependent activation of the receptor kinase c-Met is dramatically reduced in CD82-expressing cells, as is c-Met activation by its ligand HGF/ SF. CD82 expression also reduced integrin-induced activation and phosphorylation of the cytoplasmic tyrosine kinase Src, and its downstream substrates p130Cas and FAK Y861. Inhibition of c-Met expression or Src kinase function reduced matrigel invasion of PC3 cells to the same extent as CD82 expression. These data indicate that CD82 functions to suppress integrin-induced invasion by regulating signaling to c-Met and Src kinases, and suggests that CD82 loss may promote metastasis by removing a negative regulator of c-Met and Src signaling.
Introduction
KAI1/CD82 was originally identified as a suppressor of metastatic spread of tumor cells in a rat prostate model (Dong et al., 1995) . Numerous subsequent studies demonstrated a direct correlation with loss of CD82 expression and poor prognosis in human prostate cancer (Dong et al., 1996; Sridhar and Miranti, 2005) . Ubiquitous expression of CD82 prompted others to explore the possibility that loss of expression may not be limited to the prostate. Loss or low expression has been shown to correlate with poor prognosis in lung (Adachi et al., 1996) , pancreatic (Guo et al., 1996) , breast (Huang et al., 1998) , bladder (Yu et al., 1997) , colon (Lombardi et al., 1999) , esophageal (Uchida et al., 1999; Miyazaki et al., 2000) , cervical (Liu et al., 2001) , ovarian , and endometrial cancers. Downregulation of CD82 expression has also been observed in many metastatic tumor cell lines (White et al., 1998) .
KAI1/CD82 belongs to the transmembrane 4 super family (TM4SF), also referred to as tetraspanins (Sridhar and Miranti, 2005) . Tetraspanins have been implicated in the regulation of cell motility, morphology, fusion, signaling, fertilization, and differentiation (Maecker et al., 1997; Hemler, 2001 Hemler, , 2003 . In addition to CD82, loss of expression of tetraspanin molecules CD9 or CD63 also correlates with poor prognosis and increased metastasis (Higashiyama et al., 1995; Radford et al., 1995; . Enhanced expression of tetraspanins CD81 and CD151, on the other hand, have been shown to correlate with poor prognosis and contribute significantly to increased cell motility and metastasis (Testa et al., 1999; Owens and Watt, 2001; Tokuhara et al., 2001) . Tetraspanins lack intrinsic activity and their effects are mediated by protein interactions. Several different proteins have been shown to associate with CD82 (Yunta and Lazo, 2003) , including a3b1, a4b1, a5b1, and a6b1 integrins (Berditchevski and Odintsova, 1999; Berditchevski, 2001; Yunta and Lazo, 2003) ; the serine/threonine kinase PKCa (Berditchevski and Odintsova, 1999; Berditchevski, 2001; Zhang et al., 2001 ); B-cell receptors CD4, CD8, and CD19 (Imai et al., 1995; Mannion et al., 1996; Hammond et al., 1998) ; other tetraspanins including CD81, CD63, and CD9 (Vogt et al., 2002) ; receptor tyrosine kinases EGFR and ErbB2 (Odintsova et al., 2000 (Odintsova et al., , 2003 ; an Ig super family molecule EW12 (Zhang et al., 2003b) ; and a newly identified tetraspanin molecule, kitenin, which is expressed in gastric cancers (Lee et al., 2004b) .
Integrins are heterodimeric transmembrane proteins that link the extracellular matrix to intracellular cytoskeletal structures and signaling molecules (Miranti and Brugge, 2002) . Changes in integrin levels have been reported to occur during tumorigenesis and metastasis of many tumors (Clezardin, 1998) . In prostate cancer, the reported changes in integrins include increased expression levels of a3b1 and a6b1 (Schmelz et al., 2002) , loss of b4 (Davis et al., 2001) , and a decrease in a5b1c (Perlino et al., 2000) and a2b1 integrins (Dong et al., 1997) . Integrins are implicated in regulating cellular processes such as adhesion, signaling, growth and differentiation, motility, survival, and gene expression (Miranti and Brugge, 2002) . Both integrins and receptor tyrosine kinases are involved in cell migration and metastasis. Furthermore, integrins have been shown to activate several receptor tyrosine kinases in a ligandindependent manner, including EGFR, c-Met, PDGFR, and Ron (Sundberg and Rubin, 1996; Wang et al., 1996 Wang et al., , 2001 Moro et al., 1998 Moro et al., , 2002 Danilkovitch-Miagkova et al., 2000; Bill et al., 2004) . Both integrins and receptor tyrosine kinases can interact with CD82 (Hemler, 1998; Odintsova et al., 2000) . Therefore, one mechanism by which CD82 may control tumor metastasis is by regulating the function of integrins and their ability to cooperate with receptor tyrosine kinases.
CD82 has been demonstrated to regulate the activity of the receptor tyrosine kinase, EGFR. EGF-mediated signaling and wound closure were shown to be attenuated after ectopic expression of CD82 in a breast tumor cell line (Odintsova et al., 2000) . Accelerated endocytosis of the EGFR-EGF complex was suggested to be the cause for signal attenuation. Unlike breast cancer, a role for EGFR family members in prostate metastatic disease is less frequently observed. The tyrosine kinase receptor for hepatocyte growth factor/ scatter factor (HGF/SF), c-Met, on the other hand, has been implicated in promoting prostate cancer metastasis. Overexpression of c-Met has been detected in prostate cancer and is associated with conversion to androgen independence and invasion (Fixman et al., 1995; Humphrey et al., 1995; Maggiora et al., 1997; Nakashiro et al., 2003; Knudsen and Edlund, 2004) . Src signaling downstream of c-Met may regulate tumor metastasis through regulation of migration and invasion (Ponzetto et al., 1994; Rahimi et al., 1998; Mora et al., 2002; Kim et al., 2003) . Src substrates involved in migration and invasion include focal adhesion kinase (FAK) and p130Cas (Cary et al., 1998) . Inhibition of p130Cas-Crk coupling has been suggested to be required for CD82-mediated inhibition of cell migration in CD82-expressing DU145 cells (Zhang et al., 2003a) . These findings suggest that integrin and receptor tyrosine kinase signalling may be a target for CD82.
To better understand how CD82 is involved in regulating integrin-and receptor tyrosine kinasemediated signaling, we have re-expressed CD82 in a highly invasive prostate cancer cell line PC3. We have examined CD82 regulation of integrin-mediated activation of c-Met and Src family kinases and the downstream signaling molecules involved in migration, invasion, and metastasis. These studies provide a better understanding of how loss of CD82 promotes prostate cancer metastasis.
Results

CD82 expression in PC3 cells
To characterize the role of CD82 in suppressing tumor progression and metastasis, PC3 cells were stably transfected with a CD82 cDNA. Vector-transfected stable clones were generated as controls. Figure 1a shows CD82 expression in the lysates from parental PC3 cells, seven CD82 clones (CL# 3, 6, 11, 12, 13, 14, and 29) , and one vector clone (5V) after immunoblotting with anti-CD82 antibodies. The level of expression of CD82 in these tumor cell clones was comparable to the level of expression in primary prostate epithelial cells (PEC). Surface expression of CD82 was confirmed by FACS analysis (Figure 1b ) and immunofluorescent staining (Figure 1c ).
CD82 expression reduces migration and matrigel invasion
CD82 is known to associate with a3b1 and a6b1 integrins (Hemler, 1998; Berditchevski and Odintsova, 1999; Ono et al., 2000) , integrins specifically involved in adhesion to laminin. No differences in adhesion to laminin (or other matrices) between the vector-and CD82-transfected clones was observed over a 100-fold range in laminin concentrations (Figure 2a) . No cells adhered below 0.156 mg/ml laminin and a similar small number of cells (o100) adhered to 0.31 mg/ml independent of CD82 expression. Similar results were obtained when the number of cells adhering over time was measured (not shown). There were also no changes in surface expression of laminin-binding integrins a3 (not shown), a6, b4, or b1 on any of eight clones tested, as measured by FACS or biotin labeling (Figure 2b , c). PC3 cells are elongated and spindle-shaped. Expression of CD82 resulted in rounder, more cuboidal-shaped cells resembling PECs (data not shown). PC3 cells expressing 
+CD82
Vector +CD82 (clone 6, 11, or 14) or vector were plated in triplicate on the indicated concentrations of laminin for 45 min. Nonadherent cells were washed away and stained. The number of adherent cells was counted in two random fields per well, averaged, and the standard deviation calculated. There were no significant differences between the cell lines. (b) PC3 cells expressing CD82 (cl29) or vector growing in culture was labeled with biotin at 41C. Integrin a6 was immunoprecipitated and the levels of biotin labeling were monitored by blotting with antiavidin. Total levels of protein in the extracts were equal as indicated by immunoblotting for tubulin (Tub Blot). Both b1 and b4 integrins were detected in the a6 immunoprecipitates. (c) Cell surface expression of a6 and b1 integrins in vector and three CD82-expressing PC3 clones (CL# 6, 11, 29) by FACS. (d) PC3 cells stably transfected with vector (PC3) or CD82 cDNA along with primary prostate epithelial cells (PEC) were analysed for their ability to migrate towards collagen, laminin, or fibronectin in 8 mm Boyden chambers in the absence of growth factors or serum. Cells passing through the pores were stained with crystal violet and counted. (e, f) CD82-expressing PC3 clones (CL# 3, 6, 14) , vector-transfected cells (Vec), parental cells (PC3), or primary cells (PEC) were tested for their ability to invade matrigel through 8 mm Boyden chambers to laminin-coated membranes. Cells that invaded and passed through the membrane were stained, photographed, and counted.
CD82 regulates c-Met signaling SC Sridhar and CK Miranti (Figure 2e, f) . All clones expressing CD82, however, demonstrated a dramatic reduction in their invasive ability. These experiments clearly indicate that CD82 expression not only reduces migration but also lowers in vitro invasiveness in this highly invasive cell line. FACS analysis indicated there were also no changes in surface expression of other integrins including a2, a3, or a5 (not shown). Therefore, the effects of CD82 expression on cell migration and invasion is likely due to changes in signaling downstream of integrin-mediated adhesion.
CD82 regulates integrin-and ligand-induced activation of c-Met
One mechanism by which tetraspanins may control metastasis is by regulating the function of tyrosine kinases involved in cell migration and metastasis. To investigate this possibility, c-Met activation upon integrin and ligand stimulation in vector-or CD82-expressing cells was monitored. Adhesion of PC3 cells to collagen, laminin, or fibronectin, in the absence of exogenous growth factors or serum, induced tyrosine phosphorylation of c-Met. CD82 expression suppressed integrin-induced c-Met activation in all CD82-expressing PC3 clones ( Figure 3a) .
Vector-and CD82-transfected clones were treated with the c-Met ligand HGF/SF at different concentrations and the effect on ligand-induced activation of c-Met was monitored. Higher concentrations of HGF/SF were required in the CD82-expressing cells to achieve the same level of c-Met tyrosine phosphorylation observed at lower concentrations with vector control cells ( Figure 3b ). These results indicate that CD82 can regulate both integrin-and ligand-mediated activation of c-Met in PC3 cells.
CD82 does not appear to be regulating the turnover of c-Met protein. Total protein levels of c-Met, as determined by immunoblotting, were relatively unchanged. Neither were there any differences in the levels of c-Met protein over time following integrin-or ligandinduced c-Met activation between vector and CD82-expressing cells (see Supplementary data, Figure S2B ). Furthermore, no significant changes in cell surface expression of c-Met by FACS analysis ( Figure S2A ) were detected. Thus, CD82 acts to suppress the extent of c-Met activation, rather than affecting the overall levels of c-Met. To determine if c-Met and CD82 can associate with each other, their ability to colocalize within cells was assessed by immunostaining and confocal microscopy. We were unable to detect colocalization of c-Met and CD82 at either the surface or within the cell ( Figure 3c ). We were also unable to detect an association by co-immunoprecipitation (not shown). These data suggest that CD82 affects c-Met activation through an indirect mechanism.
CD82 regulates phosphorylation of Src and its substrates FAK and p130Cas
Integrins and c-Met regulate cell migration and invasion by regulating downstream signaling pathways such as Src, PI-3K/Akt, and Ras/Erk. Integrin-mediated adhesion of PC3 cells does not lead to Erk activation and the PI-3K pathway is constitutively activated (see Supplementary data, Figure S3A ). Furthermore, reexpression of CD82 did not alter signaling to Erk or to Akt ( Figure S3B ). Both integrins and c-Met have been shown to be effective in activating Src (Rahimi et al., Hauck et al., 2002; Hsia et al., 2003; Frame, 2004; Westhoff et al., 2004; Brunton et al., 2005) . To determine if CD82 is involved in signaling to Src, we investigated Src activation following integrin engagement in CD82-expressing cells. Src phosphorylation at the activation loop Y418 was monitored by immunoblotting with a phospho-specific antibody. Src activation was reduced upon integrin engagement in CD82-expressing cells (Figure 4a ). To further support these findings, Src substrates implicated in cell migration and invasion, FAK and p130Cas, were monitored. The levels of p130Cas protein were frequently observed to decrease when cells were placed in suspension independent of CD82 expression. Nonetheless, the presence of CD82 inhibited tyrosine phosphorylation of the Src substrate p130Cas (Figure 4b ) when cells were replated on matrix. Expression of CD82 in PC3 cells also reduced integrininduced phosphorylation at the Src-specific phosphorylation site Y861 in FAK, but not Y397, the FAK autophosphorylation site (Figure 4c ). Primary PEC express significant quantities of CD82 ( Figure 1a) . Correspondingly, there is reduced integrin-dependent activation of Src and p130Cas, in PECs compared to PC3 tumor cells (Figure 4a , b). Thus, CD82 may limit Src signaling in normal cells and its loss in tumor cells may enhance signaling through Src.
Inhibition of Src or c-Met blocks invasion
CD82 expression in PC3 cells reduces matrigel invasion and also reduces activation of c-Met and Src. Therefore, we tested whether c-Met and Src are also required for invasion. Parental or vector PC3 cells were pretreated with the Src kinase-specific inhibitor, SU6656 (Blake et al., 2000) , and their ability to invade matrigel was monitored. Inhibition of Src activity blocked invasion to the same extent as CD82 expression (Figure 5a, b) . were placed in suspension (S) or plated on collagen (CL), laminin (LM), or fibronectin (FN). After 1 h, the levels of (a) Src Y418, (b) p130Cas, (c) FAK Y861 or FAK Y397 phosphorylation was measured by immunoblotting of immunoprecipitates with respective phospho-specific or anti-phosphotyrosine antibodies (P-Y418, P-Tyr, P-Y861, or P-Y397 Blots). Total levels of protein in the immunoprecipitates were measured by immunoblotting of stripped blots with respective antibodies (Src, Cas, and FAK Blots).
CD82 regulates c-Met signaling SC Sridhar and CK Miranti c-Met activation might be involved in regulating integrin-mediated activation of Src is unknown. To test these models, Src activation was blocked with 2 mM SU6656 (Blake et al., 2000) and the effect on c-Met activation following integrin engagement was monitored. Blocking Src did not change integrin-mediated c-Met activation, but did block integrin-induced p130Cas phosphorylation (a Src substrate) (Figure 6a, b) . Inhibition of c-Met by si-hMet-Ad 221 or si-mMet-Ad 178 expression did not block integrin-mediated activation of Src, as measured by phosphorylation at Y418 (Figure 6c ). Thus, integrin-mediated activation of Src and c-Met in PC3 cells are independent events. However, both are required for matrigel invasion ( Figure 5 ).
Overexpression of c-Met induces invasion
To determine if CD82 expression in another prostate tumor cell line can also suppress c-Met activation, we selected stable CD82 transfectants of DU145 cells (Figure 7b) . Surprisingly, c-Met was not activated in DU145 cells by plating on matrix (Figure 7a ). Immunoblotting indicated that the levels of c-Met expression in DU145 cells are greatly reduced compared to normal PECs or PC3 cells (Figure 5c ). Correspondingly, DU145 cells, unlike PC3 cells, failed to invade matrigel in the absence of serum or growth factors (Figure 7c, d ).
Treatment with HGF was sufficient to promote DU145 invasion, but did not increase PC3 cell matrigel invasion. To better understand CD82 regulation of c-Met, we overexpressed c-Met in DU145 cells and in CD82-expressing DU145 cells (Figure 7b) . Expression of c-Met in DU145 cells was sufficient to permit matrigel invasion in the absence of HGF (Figure 7a) . Expression of CD82 suppressed HGF-induced invasion at low concentrations of HGF. High concentrations of HGF overcame the inhibitory effects of CD82 expression. Thus, CD82 affects the relative sensitivity of signaling through c-Met.
Discussion
The results from this study indicate that re-expression of CD82 in a highly invasive metastatic prostate cancer cell line, PC3, suppresses (1) cell migration on laminin and collagen, (2) both integrin-and ligand-induced activation of c-Met, (3) integrin-mediated activation of Src and two of its downstream substrates p130Cas and FAK Y861, and (4) both integrin-and HGF-mediated invasion of laminin-rich matrigel. Furthermore, inhibition of Src or c-Met function reduced integrin-mediated invasion to the same extent as CD82 expression. Overexpression of c-Met was sufficient to induce HGF-independent invasion and CD82 expression suppressed c-Met-mediated invasion. Based on these results, we propose a model whereby CD82 functions to suppress integrin-induced invasion by regulating c-Met and Src kinases (Figure 8 ). These data suggest that loss of CD82 expression in prostate tumors promotes metastasis by permitting more efficient activation of Src and c-Met by both integrins and ligand. CD82, like other tetraspanins, has been reported to associate with several integrins, namely a3b1, a4b1, a5b1, and a6b1 (Berditchevski and Odintsova, 1999; Berditchevski, 2001; Yunta and Lazo, 2003) . Previous studies have shown that the role of tetraspanins is not to regulate integrin expression, but to modulate integrin function and as such have been termed 'molecular facilitators' (Maecker et al., 1997; Hemler, 2001 ). However, a few papers have suggested that CD82 can regulate cell adhesion to fibronectin (Takaoka et al., 1998; Liu et al., 2003) or laminin (He et al., 2005) . In one report, CD82 expression was found to downregulate the expression of a6 integrin in DU145 cells (He et al., 2005) . We monitored the cell surface expression of several different integrins in parental, vector, and eight different clones of CD82-expressing PC3 cells. We used two different methods, FACS and surface biotinylation, two different a6 antibodies, and two different conditions, serum starved or adherent to laminin. We found , and CD82 CL8 clones (9, 11) and the levels of CD82 (CD82 Blot) in CL8, CL8 clones (7, 9, 11), and vector-transfected cells (DuV) were monitored by immunoblotting. (c) PC3 clones (cl11, cl29) stably transfected with CD82 or vector (5V) were tested for their ability to invade matrigel through 8 mm Boyden chambers to a laminincoated membrane in the absence (HGFÀ) or presence of 25 ng/ml HGF. Cells that invaded and passed through the membrane were stained and counted. (d) Parental DU145 cells (DU145) or DU145 cells over expressing c-Met (DU þ met), CD82 (DUcl8), or both c-Met and CD82 (DUcl8 þ met) were allowed to invade matrigel in the absence (HGFÀ) or presence of 25 or 100 ng/ml HGF. Cells that invaded were stained and counted.
CD82 regulates c-Met signaling SC Sridhar and CK Miranti no differences in integrin expression, not even with a6. We also did not observe any differences in the ability of the cells to adhere to different matrices including laminin. This discrepancy could be due to differences in cell lines. In our hands, DU145 cells adhere poorly to laminin and the levels of a6 integrin are much lower than in PC3 cells (see Supplementary data, Figure S1 ). DU145 cells also did not invade laminin-containing matrigel in the absence of serum or growth factors, but PC3 cells did. Another possibility is that the level of CD82 expression could vary between these studies. We selected clones that expressed similar or lower levels of CD82 than normal primary PEC. Overexpression of CD82 can lead to apoptosis (Schoenfeld et al., 2004) . Thus our data indicate that in highly invasive cells that adhere, migrate, and invade well on laminin, CD82 expression does not change integrin expression, but rather acts downstream of integrin engagement. c-Met, the receptor for HGF/SF, is known to regulate migration and invasion and has been implicated in promoting metastasis in many different kinds of cancers (Pisters et al., 1995; Birchmeier et al., 1997 Birchmeier et al., , 2003 Wang et al., 2001) , including prostate cancer (Humphrey et al., 1995; Nishimura et al., 1998; Knudsen et al., 2002; van Leenders et al., 2002; Nakashiro et al., 2003; Knudsen and Edlund, 2004) . Previous studies in a mammary tumor cell line demonstrated that CD82 expression attenuated EGF-mediated EGFR signaling and reduced migration (Odintsova et al., 2000) . In PC3 or DU145 cells, we did not observe significant changes in integrin-induced activation of EGFR or EGFR levels due to CD82 expression (not shown). We have not measured the response of EGFR to EGF. We did observe a decrease in both integrin-and ligand-induced c-Met activation when CD82 is expressed, but neither resulted in a change in overall c-Met levels. These data suggest that there may be a fundamental difference between how EGFR and c-Met are regulated or that these cell types behave differently. In prostate cancer, c-Met, rather than EGFR or ErbB, has been the tyrosine kinase receptor implicated in metastasis (Humphrey et al., 1995; Pisters et al., 1995; Nishimura et al., 1998; Knudsen et al., 2002; van Leenders et al., 2002; Nakashiro et al., 2003; Knudsen and Edlund, 2004) . The role of EGFR/Erb2 in prostate cancer, unlike breast cancer, remains controversial (Maygarden et al., 1992; De Miguel et al., 1999; Skacel et al., 2001; Di Lorenzo et al., 2002) . Thus, CD82 may regulate different receptors in different cell or tumor types.
Previous studies have suggested that c-Met and laminin integrins may interact to regulate invasion (Trusolino et al., 2001; Chung et al., 2004) . Our studies found that PC3 cells express higher levels of c-Met relative to DU145 cells and integrins were incapable of activating c-Met in DU145 cells. Consequently, in our assays, DU145 cells failed to invade through matrigel in the absence of serum or growth factors. However, we and others have demonstrated that DU145 cells will invade matrigel if HGF/SF is present (Nishimura et al., 1998 (Nishimura et al., , 1999 Davies et al., 2004) . CD82 expression in DU145 cells was able to suppress HGF-mediated invasion. Low concentrations of HGF were not sufficient to overcome the effects of CD82. However, high concentrations of HGF reversed CD82-mediated suppression of invasion. Furthermore, overexpression of c-Met was sufficient to promote ligand-independent, integrin-mediated invasion of matrigel. These data strongly support the role of CD82 in regulating c-Met activation.
Signaling through Src has been proposed to be involved in regulating cell migration and invasion by integrins (Sieg et al., 2000; Hauck et al., 2002; Hsia et al., 2003; Frame, 2004; Westhoff et al., 2004; Brunton et al., 2005) . Two downstream targets of Src, FAK and p130Cas, have been proposed to be required for integrin-mediated migration (Vuori et al., 1996; Klemke et al., 1998; Hauck et al., 2002) . Our studies indicate that expression of CD82 in PC3 cells downregulates this pathway. A similar study in DU145 cells indicated that CD82 expression also modified this pathway, but through a different mechanism (Zhang et al., 2003a) . While we observe a direct affect on Src signaling and its ability to efficiently phosphorylate down stream substrates, the study of Zhang et al. demonstrated no involvement of Src kinase activity, but rather a loss in p130Cas expression. These differences could be due to differences in cell lines, the integrins expressed, and the mechanisms they use to regulate cell movement. This may also reflect a difference in signaling pathways involved in regulating haptotactic migration on a twodimensional surface versus the capacity to migrate and Figure 8 Model for CD82 regulation of invasion. CD82 functions to limit both integrin and ligand-induced activation of the receptor tyrosine kinase c-Met. Therefore, it is predicted that loss of CD82 during late-stage tumorigenesis permits increased activation of c-Met through both integrin and ligand. CD82 also independently decreases integrin-induced Src activation. Concurrently, increased signaling through Src leads to increased activation of downstream substrates, p130Cas and FAK, which regulate cell migration and invasion. The mechanism by which c-Met enhances invasion is not known.
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invade in a three-dimensional network. Our studies have clearly demonstrated that Src is required for invasion and that CD82 suppresses both Src and invasion. Interestingly, expression of CD82 was not sufficient to completely block invasion (not to the level seen in normal cells), and neither was suppression of Src. In fact, inhibition of Src in the presence of CD82 did not further suppress invasion. These data indicate that other signaling events not involved in this pathway are also involved in regulating invasion. PC3 cells harbor a pTEN mutation which results in increased signaling through the PI-3K and Akt pathway. This pathway has also been linked to increased invasion (Tamura et al., 1999; Brader and Eccles, 2004) . However, expression of CD82 failed to inhibit this signaling pathway, suggesting the possibility that this may be a non-CD82-regulated invasion pathway. Our data support recent evidence for the existence of crosstalk between integrins and c-Met (Wang et al., 1996 (Wang et al., , 2001 Trusolino et al., 2001) . Our data further suggest that CD82 may be regulating this crosstalk. The mechanism by which integrins activate receptor tyrosine kinases has not been completely resolved. One model proposes that Src activation by integrins leads to phosphorylation of the receptor cytoplasmic domain (Danilkovitch-Miagkova et al., 2000; Moro et al., 2002) ; however, this is not always the case (Bill et al., 2004) . In PC3 cells, integrin-mediated activation of c-Met was not dependent on Src activity. Prior studies indicate that ligand-independent activation of receptor kinases is required for signaling downstream of integrins (Moro et al., 1998; Bill et al., 2004) . However, we found that inhibition of c-Met had no effect on integrin-induced Src activation per se. We cannot rule out the possibility that c-Met could regulate Src activity indirectly by affecting its localization or ability to target downstream substrates.
Previous studies have suggested that CD82 may act positively to activate signaling to Src and FAK (Lagaudriere-Gesbert et al., 1998; Berditchevski and Odintsova, 1999; Jee et al., 2003) . In T cells, anti-CD82 antibodies were shown to activate p56lck, a member of Src kinase family; however, this was only observed in the context of costimulation of the T-cell receptor and was not observed upon cell adhesion to anti-CD82 antibodies (Lagaudriere-Gesbert et al., 1998) . In CD82-transfected DU145 cells, anti-CD82 antibody enhanced Src kinase activity in cell-cell aggregates in suspension independently of integrins (Jee et al., 2003) . However, these two examples do not address the same biological question; what is the role of CD82 in regulating integrin functions. On the other hand, clustering of CD82 in MDA-MB-231 breast cancer cells attached to collagen was shown to enhance tyrosine phosphorylation of FAK (Berditchevski and Odintsova, 1999 ). When we replicated this assay in PC3 cells expressing CD82, we did not observe any enhancement of c-Met, p130Cas, Src, or FAK activation (not shown). Enhancement of Src or FAK activity was also not observed in CD82-transfected DU145 cells upon integrin engagement (Zhang et al., 2003a) .
Both c-Met and Src are required for invasion and CD82 blocks c-Met, Src, and invasion. These data indicate that loss of CD82 likely increases signaling through c-Met and Src to promote increased invasion and metastasis in vivo. This has important implications for therapeutic targeting. Replacement of genes to restore expression is much more difficult than inhibiting the activity of active genes. Therefore, these findings indicate that targeting of c-Met and/or Src therapeutically could result in reduced metastasis by suppressing the same pathway that KAI1/CD82 normally acts to suppress.
Materials and methods
Antibodies
Antibodies against c-Met for immunoprecipitation (Met-D1) and for surface expression (Met-3) were obtained from Dr Brian Cao at the monoclonal antibody core facility at the Van Andel Institute (Hay et al., 2003) . TS82b, antibody to CD82 used for immunoblotting, was a generous gift from Dr Eric Rubinstein (INSERM, Villejiuf, France). The CD82 antibody used for immunostaining and FACS (BD-CD82) and anti-a6 integrin antibodies were purchased from BD-Pharmingen. The monoclonal anti-Src antibody 327 has been described previously (Lipsich et al., 1983) . The anti-phosphotyrosine monoclonal antibody 4G10 was provided by Tom Roberts (Dana Faber Cancer Institute, Boston, MA, USA). Phosphospecific antibodies against Erk1/2 (T202/Y204) and Akt (S473) were from Cell Signaling (NEN). Total Erk antibody was from Transduction Labs and total Akt antibody was described previously (Bill et al., 2004) . Anti-phosphotyrosine antibodies specific to Src pY 418 , FAK pY 397 , and FAK pY 861 were from Biosource International Inc. c-Met antibodies for immunostaining and FAK antibodies used for immunoprecipitation were from Santa Cruz Biotechnology and antibodies to the C-terminal end of FAK (FRNK) has been described elsewhere (Bill et al., 2004) . Antibodies to p130Cas were purchased from BD Transduction labs. Anti-integrin antibodies a3 and b4 were from Chemicon, and antibodies to b1 (AIIB2) were from the Iowa Hybridoma Bank (Ames, IA).
Cell culture and transfections
Primary PEC were obtained from Dr Beatrice Knudsen, Fred Hutchinson Cancer Research Center, and cultured as previously described (Gmyrek, 2001 ). PC3 and DU145 cells were obtained from American Type Culture Collection (ATCC). PC3 cells were maintained in F12K medium (Invitrogen) and DU145 cells were maintained in DMEM (Invitrogen). Both media were supplemented with 10% fetal bovine serum (Gibco), 2 mM glutamine, and 50 U of penicillin and 50 mg of streptomycin/ml. PC3 or DU145 cells were transfected with a plasmid construct pCDNA3.1(PAL)N-flag.CD82, obtained from Dr Kurt Cannon, Yale University (Cannon and Cresswell, 2001) . DU145 or PC3 cells at 10 6 cells per 10-cm diameter plate were transfected with 10 mg of total DNA (1 mg of CD82 or 1 mg of vector plus 9 mg pBluescript DNA) using LT1 lipid as described by the manufacturer (Pan-Vera). At 6 h following transfection, the culture media were changed to regular F12K medium with supplements and replaced 48 h later with the same culture medium containing puromycin (2 mg/ml). Puromycin-resistant clones were picked 10 days later and screened for CD82 expression by immunoblotting with TS82b antibodies. CD82-expressing clones were maintained in growth medium containing puromycin and used in assays described below. DU145 or CD82-expressing DU145 cells were transfected as above with 1 mg of plasmid pCMVc-hMet plasmid (Rong et al., 1992) , 1 mg pSV-neo plasmid, and 8 mg pBluescript DNA. Cells were selected in 1 mg/ml G418, and neomycin-resistant clones were selected and screened for both CD82 and c-Met expression. For ligand stimulation of c-Met, cells were serum starved overnight and then treated for 5-10 min with increasing concentrations of HGF/SF (Calbiochem) prior to lysis.
Adhesion to matrix
Adhesion to extracellular matrices was routinely performed as described by Miranti (2002) . Briefly, cells were serum starved 18-24 h, trypsinized, and placed in suspension for 30 min. Cells were placed on plates coated with 10 mg/ml of Collagen I (rat tail, BD Biosciences), Laminin (mouse, Invitrogen), or Fibronectin (BD Biosciences). A suspension control was maintained at 371C. After 45-60 min when the cells begin to adhere and spread, the cells were subjected to lysis with RIPA buffer (10 mM Tris (pH 7.2), 158 mM NaCl, 1 mM EDTA, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, 1% Triton X-100, 1 mM Na 3 VO 4 , 1 mM phenylmethyl sulfonyl fluoride (PMSF), 5 mg of aprotinin/ml, 5 mg of pepstatin/ml, 5 mg of leupeptin/ml, and 1 mM benzamide). Suspension samples were subjected to lysis at the same time. After lysis, adherent and suspension samples were passed through a 27 gauge needle. All lysed samples were subjected to centrifugation at 13 000 g for 10 min.
For Src inhibition studies, PC3 cells were pretreated with DMSO or 2 mM SU6656 (Calbiochem) during the last 6 h of the 24 h starvation phase and maintained during adhesion to matrices.
Adhesion assay
Vector and CD82-expressing PC3 cells were starved and placed in suspension as outlined above. 96-well plates were coated with serial dilutions of laminin in triplicate from 10 to 0.078 mg/ml. Cells were allowed to adhere for 45 min. Nonadherent cells were removed by washing with PBS and cells were fixed and stained with 0.09% crystal violet stain (Chemicon) for 10 min. Alternatively, cells were allowed to adhere to 96 wells coated with 10 mg/ml laminin for various times, ranging from 10 min to 1 h. The number of cells in two random microscopic fields per well were photographed and counted.
Immunoprecipitation and immunoblotting
Protein concentrations of the samples were determined using the bicinchoninic acid assay (Pierce). Immunoprecipitation mixtures containing 500-1000 mg protein were incubated with the appropriate antibodies for 3 h at 41C with either protein Aor protein G-conjugated agarose beads (Pierce) to capture the complexes. All immunoprecipitated complexes were washed three times with their respective lysis buffer. Immunoprecipitated samples from adhesion assays were resuspended in 2 Â SDS sample buffer, boiled for 5-15 min. For immunoblotting of CD82 in cell lysates, 50 mg of protein was resuspended in 2 Â sample buffer under nonreducing conditions. All resuspended samples were then subjected to SDS-polyacrylamide gel electrophoresis, transferred to a polyvinylidene difluoride membrane (PVDF). The PVDF membranes were blocked with 5% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 for 2 h, followed by 2 h incubation with the appropriate primary antibodies. After several washes, blots were incubated with a horseradish peroxidase-conjugated secondary antibody (Bio-Rad) for 1 h and visualized with a chemiluminescence reagent (NEN). Blots were stripped in lowpH 2% SDS at 651C for 60 min, rinsed, and reprobed for total levels of protein in the immunoprecipitates or cell lysates.
Migration and invasion assays
For migration assays, the underside of the membrane of the upper chamber of 8 mm transwell migration chambers (Corning) were coated with 10 mg/ml of collagen I, laminin, or fibronectin. Approximately 50 000-70 000 serum-starved cells of the vector-or the CD82-transfected PC3 cells were added to the upper chamber. For Src inhibition studies, cells were pretreated with DMSO or 2.5 mM SU6656 (Calbiochem) during the 18-24 h starvation phase. The cells were incubated at 371C, and after 3 h, the cells were washed, then fixed and stained with 0.09% crystal violet stain (Chemicon) for 10 min. Cells remaining on the upper side of the membrane were removed with a cotton swab. Stained cells that had migrated through the membrane to the underside were visualized on a Nikon TE300 microscope and pictures taken using a CCD camera (Hammamatsu) attached to an Apple Macintosh G4. Images were compiled using OpenLab software (Improvision) Pictures were collected from three different fields of each chamber and counted. Invasion assays were performed on a matrigel invasion chambers (BD Biocoat, Beckton Dickinson Labware). The invasion assays were set up identically to the migration assays except that cells were fixed and stained after 72 h. Pictures of the invaded cells were taken using Nikon TE300 microscope attached to a camera as described above. For both migration and invasion assays, the number of cells in each of three fields for each assay were counted and the standard error was calculated and plotted.
Antibody crosslinking
Cells were plated on laminin, and after 1 h unattached cells were washed with DMEM. Then, 25 mg/ml mouse IgG (Pierce) or 25 mg/ml of TS82b antibodies was added. Cells were incubated at 371C for 2 h, washed with DMEM and incubated with secondary rabbit anti-mouse antibodies at 2.5 mg/ml (Pierce) for 1 h. Cells were washed and lysed in RIPA.
Immunofluorescent staining
Immunofluorescent staining protocols were performed similar to Lee et al. (2004a) with some modifications. Round cover slips were coated with Collagen I or laminin (10 mg/ml, final concentration) overnight in a six-well dish. Matrix-coated cover slips were blocked with 1% BSA in PBS. Following a standard adhesion protocol (Miranti, 2002) , around 50 000 cells of the vector-or CD82-transfected PC3 cells were plated on the cover slips. Adherent cells were fixed with 4% paraformaldehyde in PBS for 10 min and permeabilized with 0.2% Triton-X for 3 min. Nonspecific binding was blocked by incubating with 1% normal goat serum for 2 h. c-Met was detected with anti-c-Met antibodies from Santa Cruz Biotechnology and CD82 was detected with anti-CD82 antibodies (BD-Pharmingen). Secondary antibodies were either Alexa488-conjugated (green) or Alexa568-conjugated (red) anti-mouse secondary antibodies (Molecular Probes). Cells were counterstained with Hoechst 33258 (at 10 mg/ml) for visualization of the nuclei and mounted on a slide with 10 ml of p-Phenylenediamine PPD, an antifade agent (Sigma). Stained cells were visualized either on a Nikon TE300 microscope equipped for epi-fluorescence using a CCD camera (Hammamatsu) attached to an Apple Macintosh G4 and OpenLab software (Improvision) or with a Zeiss LSM510 Confocal Scope and Zeiss LSM Imaging Software.
Surface expression of CD82, integrins, and c-Met were analysed using a FACS Caliber (Becton Dickinson). Approximately 1 Â 10 6 cells were collected by trypsinization and stained with the appropriate primary antibody (BD-CD82, integrins a3, a6, or b1, or Met-3). After staining with FITCconjugated secondary antibodies, the samples were analysed for surface expression by FACS Caliber. The level of surface expression was normalized to that observed with cells treated with IgG control antibodies. The results were generated using FACS analysis software.
Surface biotinylation
Cells were plated on laminin or were left attached to culture plates after serum starvation. Unattached cells were washed away and cells were placed on ice. EZ-link NHC-LC Biotin (Pierce, Rockford, IL, USA) at 0.5 mg/ml in PBS was added to the adherent cells and incubated at 41C for 2 h. Cells were lysed with 1 Â RIPA and a6 integrin was immunoprecipitated. Biotin labeling was detected by immunoblotting with extravidin-peroxidase conjugate (Sigma).
shRNA inhibition of c-Met Generation of the adenoviral vectors and virus for the expression of human c-Met shRNAs has been previously described (Shinomiya et al., 2004 0 . The si-mMet-Ad 178 virus was designed to inhibit mouse c-Met, but shares homology with 16 of 19 bases to human c-Met and was efficient at inhibiting human c-Met expression in both DU145 and PC3 cells (data not shown). After 2-3 days, cells were used in adhesion or invasion assays. The levels of c-Met expression in each assay were monitored by immunoblotting.
